180 related articles for article (PubMed ID: 35138911)
1. CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function.
Ruggiero E; Carnevale E; Prodeus A; Magnani ZI; Camisa B; Merelli I; Politano C; Stasi L; Potenza A; Cianciotti BC; Manfredi F; Di Bono M; Vago L; Tassara M; Mastaglio S; Ponzoni M; Sanvito F; Liu D; Balwani I; Galli R; Genua M; Ostuni R; Doglio M; O'Connell D; Dutta I; Yazinski SA; McKee M; Arredouani MS; Schultes B; Ciceri F; Bonini C
Sci Transl Med; 2022 Feb; 14(631):eabg8027. PubMed ID: 35138911
[TBL] [Abstract][Full Text] [Related]
2. Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML.
Lo Presti V; Meringa A; Dunnebach E; van Velzen A; Moreira AV; Stam RW; Kotecha RS; Krippner-Heidenreich A; Heidenreich OT; Plantinga M; Cornel A; Sebestyen Z; Kuball J; van Til NP; Nierkens S
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580329
[TBL] [Abstract][Full Text] [Related]
3. WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma.
van Amerongen RA; Hagedoorn RS; Remst DFG; Assendelft DC; van der Steen DM; Wouters AK; van de Meent M; Kester MGD; de Ru AH; Griffioen M; van Veelen PA; Falkenburg JHF; Heemskerk MHM
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35728869
[TBL] [Abstract][Full Text] [Related]
4. A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells.
Jaigirdar A; Rosenberg SA; Parkhurst M
J Immunother; 2016 Apr; 39(3):105-16. PubMed ID: 26938944
[TBL] [Abstract][Full Text] [Related]
5. Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency.
Lahman MC; Schmitt TM; Paulson KG; Vigneron N; Buenrostro D; Wagener FD; Voillet V; Martin L; Gottardo R; Bielas J; McElrath JM; Stirewalt DL; Pogosova-Agadjanyan EL; Yeung CC; Pierce RH; Egan DN; Bar M; Hendrie PC; Kinsella S; Vakil A; Butler J; Chaffee M; Linton J; McAfee MS; Hunter DS; Bleakley M; Rongvaux A; Van den Eynde BJ; Chapuis AG; Greenberg PD
Sci Transl Med; 2022 Feb; 14(631):eabg8070. PubMed ID: 35138909
[TBL] [Abstract][Full Text] [Related]
6. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.
Ochi T; Fujiwara H; Okamoto S; An J; Nagai K; Shirakata T; Mineno J; Kuzushima K; Shiku H; Yasukawa M
Blood; 2011 Aug; 118(6):1495-503. PubMed ID: 21673345
[TBL] [Abstract][Full Text] [Related]
7. Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers.
Li Q; Hu W; Liao B; Song C; Li L
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798537
[TBL] [Abstract][Full Text] [Related]
8. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.
Ochi T; Nakatsugawa M; Chamoto K; Tanaka S; Yamashita Y; Guo T; Fujiwara H; Yasukawa M; Butler MO; Hirano N
Cancer Immunol Res; 2015 Sep; 3(9):1070-81. PubMed ID: 25943533
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs.
Fujiki F; Morimoto S; Nishida Y; Tanii S; Aoyama N; Inatome M; Inoue K; Katsuhara A; Nakajima H; Nakata J; Nishida S; Tsuboi A; Oka Y; Oji Y; Sogo S; Sugiyama H
Cancer Immunol Immunother; 2023 Jul; 72(7):2347-2356. PubMed ID: 36939853
[TBL] [Abstract][Full Text] [Related]
10. Establishment of a novel platform cell line for efficient and precise evaluation of T cell receptor functional avidity.
Morimoto S; Fujiki F; Kondo K; Nakajima H; Kobayashi Y; Inatome M; Aoyama N; Nishida Y; Tsuboi A; Oka Y; Nishida S; Nakata J; Hosen N; Oji Y; Sugiyama H
Oncotarget; 2018 Sep; 9(75):34132-34141. PubMed ID: 30344927
[TBL] [Abstract][Full Text] [Related]
11. Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor.
Asai H; Fujiwara H; An J; Ochi T; Miyazaki Y; Nagai K; Okamoto S; Mineno J; Kuzushima K; Shiku H; Inoue H; Yasukawa M
PLoS One; 2013; 8(2):e56820. PubMed ID: 23441216
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells.
Thomas S; Xue SA; Cesco-Gaspere M; San José E; Hart DP; Wong V; Debets R; Alarcon B; Morris E; Stauss HJ
J Immunol; 2007 Nov; 179(9):5803-10. PubMed ID: 17947653
[TBL] [Abstract][Full Text] [Related]
13. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization.
Rezvani K; Brenchley JM; Price DA; Kilical Y; Gostick E; Sewell AK; Li J; Mielke S; Douek DC; Barrett AJ
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8799-807. PubMed ID: 16361568
[TBL] [Abstract][Full Text] [Related]
14. An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells.
Kondo K; Fujiki F; Nakajima H; Yatsukawa E; Morimoto S; Tatsumi N; Nishida S; Nakata J; Oka Y; Tsuboi A; Hosen N; Oji Y; Sugiyama H
J Immunother; 2016 Apr; 39(3):127-39. PubMed ID: 26938946
[TBL] [Abstract][Full Text] [Related]
15. Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.
Calviño C; Ceballos C; Alfonso A; Jauregui P; Calleja-Cervantes ME; San Martin-Uriz P; Rodriguez-Marquez P; Martin-Mallo A; Iglesias E; Abizanda G; Rodriguez-Diaz S; Martinez-Turrillas R; Illarramendi J; Viguria MC; Redondo M; Rifon J; Villar S; Lasarte JJ; Inoges S; Lopez-Diaz de Cerio A; Hernaez M; Prosper F; Rodriguez-Madoz JR
Front Immunol; 2023; 14():1270843. PubMed ID: 37795087
[TBL] [Abstract][Full Text] [Related]
16. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
[TBL] [Abstract][Full Text] [Related]
17. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR.
Okamoto S; Mineno J; Ikeda H; Fujiwara H; Yasukawa M; Shiku H; Kato I
Cancer Res; 2009 Dec; 69(23):9003-11. PubMed ID: 19903853
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous in vitro generation of CD8 and CD4 T cells specific to three universal tumor associated antigens of WT1, survivin and TERT and adoptive T cell transfer for the treatment of acute myeloid leukemia.
Sohn HJ; Lee JY; Lee HJ; Sohn DH; Cho HI; Kim HJ; Kim TG
Oncotarget; 2017 Jul; 8(27):44059-44072. PubMed ID: 28477011
[TBL] [Abstract][Full Text] [Related]
19. Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA.
Campillo-Davo D; Versteven M; Roex G; Reu H; Heijden SV; Anguille S; Berneman ZN; Tendeloo VFIV; Lion E
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 31972992
[TBL] [Abstract][Full Text] [Related]
20. Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS.
Tawara I; Kageyama S; Miyahara Y; Fujiwara H; Nishida T; Akatsuka Y; Ikeda H; Tanimoto K; Terakura S; Murata M; Inaguma Y; Masuya M; Inoue N; Kidokoro T; Okamoto S; Tomura D; Chono H; Nukaya I; Mineno J; Naoe T; Emi N; Yasukawa M; Katayama N; Shiku H
Blood; 2017 Nov; 130(18):1985-1994. PubMed ID: 28860210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
